An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions

Human Anti-IgG1 Hinge Autoantibodies Reconstitute the Effector Functions of Proteolytically Inactivated IgGs

(2014) R. J. Brezski et al.   JOURNAL OF IMMUNOLOGY

A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo

(2014) Randall J Brezski et al.   mAbs

Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies

(2014) Andrew J.S. Furness et al.   TRENDS IN IMMUNOLOGY

Macrophage Regulation of Tumor Responses to Anticancer Therapies

(2013) Michele De Palma et al.   CANCER CELL

Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients

(2013) R. M. Srivastava et al.   CLINICAL CANCER RESEARCH

Engineered Protease-resistant Antibodies with Selectable Cell-killing Functions

(2013) Michelle Kinder et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies

(2013) Jeong M. Kim et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

(2013) Yannick Bulliard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Impact of Immune Complex Size and Glycosylation on IgG Binding to Human Fc Rs

(2013) A. Lux et al.   JOURNAL OF IMMUNOLOGY

Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

(2013) M. J. Selby et al.   Cancer Immunology Research

Tumor-Associated Macrophages Promote Invasion while Retaining Fc-Dependent Anti-Tumor Function

(2012) K. D. Grugan et al.   JOURNAL OF IMMUNOLOGY

Avidity confers FcγR binding and immune effector function to aglycosylated immunoglobulin G1

(2012) Thomas C. Nesspor et al.   JOURNAL OF MOLECULAR RECOGNITION

The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge

(2012) Randall J. Brezski et al.   mAbs

Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314

(2012) Ralf Kircheis et al.   mAbs

Mouse model recapitulating human Fc  receptor structural and functional diversity

(2012) P. Smith et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab

(2011) J. Pander et al.   CLINICAL CANCER RESEARCH

Interaction with Fc RIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody

(2011) A. L. White et al.   JOURNAL OF IMMUNOLOGY

Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response

(2010) R. Abes et al.   BLOOD

The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity

(2010) SaeGwang Park et al.   CANCER CELL

Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions

(2010) Gregory L. Moore et al.   mAbs

Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm

(2010) Subhra K Biswas et al.   NATURE IMMUNOLOGY

"Complementing" Toll Signaling

(2010) J. C. Kagan   Science Signaling

Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab

(2009) S. P. Hilchey et al.   BLOOD

Optimization of Fc-mediated effector functions of monoclonal antibodies

(2009) William R Strohl   CURRENT OPINION IN BIOTECHNOLOGY

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

(2009) Tanja Schneider-Merck et al.   JOURNAL OF IMMUNOLOGY

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

(2009) Jolien Tol et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge

(2009) R. J. Brezski et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Specificity and affinity of human Fc  receptors and their polymorphic variants for human IgG subclasses

(2008) P. Bruhns et al.   BLOOD

Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40

(2008) E Oflazoglu et al.   BRITISH JOURNAL OF CANCER

Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities

(2008) A. Natsume et al.   CANCER RESEARCH

When binding is enough: nonactivating antibody formats

(2008) Aran F Labrijn et al.   CURRENT OPINION IN IMMUNOLOGY

Optimization of antibody binding to Fc RIIa enhances macrophage phagocytosis of tumor cells

(2008) J. O. Richards et al.   MOLECULAR CANCER THERAPEUTICS

Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid

(2007) Mary H. Ryan et al.   MOLECULAR IMMUNOLOGY